茶叶抗癌研究二十年

Twenty Years Period in the Investigation on the Anticarcinogenic Activity of Tea

对茶叶抗癌研究的世界进展进行了分析和综述。从1987年日本富田熏最早报道茶叶提取物可以抑制人体癌细胞起，全世界约发表了4000～5000篇关于茶叶抗癌的研究论文。作者将这些研究分为四个阶段：八十年代后期到九十年代中期主要集中在活体外、活体内以及临床实验，九十年代中期到新世纪初主要在流行病学研究和抗癌机理的研究，新世纪初继续进行抗癌机理研究同时进行活性成分在动物和人体内的代谢、运转和归宿的研究，从2004年起开始了儿茶素类化合物的结构修饰和改造以期提高其生物可利用性和生物活性。本文重点对2003年以来的文献分流行病学实验、抗癌机理、儿茶素类化合物在动物和人体中代谢与归宿、儿茶素类化合物的结构修饰和改造与生物活性等几个方面进行了综述，并就茶叶抗癌的应用前景进行了讨论。

The progress in the investigation on anticarcinogenic activity of tea polyphenols in the world was analyzed and reviewed in this paper. The inhibitory activity of tea extracts on the human cancer cell was firstly reported by Fujiki H in 1987 in Japan. Since then, around 5000 papers on the anticarcinogenic activity of tea were published in the world. According to the published results of investigation, four stages were divided by the author. From the period of the end of 1980＇s to the middle of 1990＇s, the major investigation was focused on the in vitro and in vivo investigation and clinical investigation. From the period of the middle of 1990＇s to the beginning of 21 Century, the major investigation was focused on the epidemiological investigation and the anticarcinogenic mechanism. Since the beginning of 21 st Century, investigation was continuing on the anticarcinogenic mechanism on the first hand, and the metabolism and fate of catechins in the animal and human body were investigated. Since 2004, the investigation on the modification of chemical structure of tea catechins was conducted for the purpose of improving the bioavailability, stability and bioactivity of tea catechins in human body. This paper is mainly reviewed from the published literature after 2003 from the following five parts： results on the epidemiological investigations, anticarcinogenic mechanism, the active components of anticarcinogenic activity in tea, results on the metabolism and fate of tea catechins in animal and human body, modification of chemical structure of tea cateehins and its bioavailability and bioactivity.